Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Rumble Announces Final Results of Exchange Offer for Northern Data
-
Lim Meng Hoong: AI Is Entering a New Era of Scientific Infrastructure, Insights from Science x AI Summit 2026
-
Macau Tea Beverage Brand 'Cha Yu' Redefines Local Flavors with Original Recipes and Signature Cloud Milk Tea
-
Solidion Technology Announces $35 Million Private Placement of Common Stock Priced Above Market Under Nasdaq Rules
-
GNI Group to Acquire Ayumi Pharmaceutical Holdings, Expanding Its Position as a Global Biopharmaceutical Company
-
LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China
-
Odysight.ai® Establishes At-The-Market (ATM) Program of up to $20 Million to Enhance Financial Flexibility
-
NAVER Expands AI Infrastructure With NVIDIA to Serve Surging Global AI Demand
-
NVIDIA and SK hynix Announce Multiyear Technology Partnership to Advance Memory for AI Factories
-
SK Telecom and NVIDIA Build AI Infrastructure to Power Korea’s AI Innovation
-
Entrata Collaborates with OpenAI to Define the Future of Autonomous Property Management
-
Diasome Presents Phase 2b Data Demonstrating HDV™-Insulin Lispro Maintains Glycemic Control While Reducing Hypoglycemia in Adults with Type 1 Diabetes
-
Canadian Employers Invited to Create 10,000 New Opportunities Through National Inclusive Hiring Campaign
-
GoHealth, Inc. to strengthen its position ahead of AEP 2026 through Restructuring Process supported by key stakeholders
-
Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss
-
Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in p
-
Boehringer Ingelheim’s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting improved metabolic
-
Antag Therapeutics presents positive Phase 1 results at the 2026 Scientific Sessions of the American Diabetes Association for AT7687, a first-in-class GIPR antagonist
-
CREDIT AGRICOLE S.A. ANNOUNCES REDEMPTION OF ¥84,200,000,000 Japanese Yen Callable Senior Non-Preferred Bonds issued on June 3, 2021 (ISIN: JP525022AM69)
-
Casino Group Communication
-
Dietz & Watson Expands Its Premium Deli Chicken Lineup with Launch of Heritage Roast and Cantina Chicken Breast at IDDBA 2026
-
Dietz & Watson Expands Its Premium Deli Chicken Lineup with Launch of Heritage Roast and Cantina Chicken Breast at IDDBA 2026
-
MemeToro Price Prediction: $1 Talk Returns as Presale Buyers Bet on MemeToro AI Agent Solutions
-
See What the Market Is Talking About — Before It Moves
-
Unlocking the Americas: Air Canada and Abra Group Sign Memorandum to Expand Travel and Connectivity between Canada, Latin America and Beyond
-
Crypto News Today: AlphaPepe Presale Hits 9300 Holders While Bitcoin Price Prediction Targets $50,000
-
Communiqué Orange : Orange signs a joint agreement to acquire SFR, a decisive step that will reinforce its leadership in France
-
Communiqué Orange : Signing of a Memorandum of Understanding for the acquisition of SFR
-
Bouygues Telecom takes a major step forward for its future growth by signing, alongside Free-iliad Group and Orange, a Memorandum of Understanding with Altice France with a view to acquiring SFR
-
Signing of a Memorandum of Understanding for the acquisition of SFR
-
Real-World Evidence of Eversense 365 Presented at ADA Demonstrating Strong Performance and Patient Impact in Both Open and Closed Loop Systems
-
Bittam Launches No-KYC Crypto Perpetual Futures Trading with 200x Leverage and ＄100 Deposit Bonus
-
Cyndee Haydon Named Among 2026 Best Real Estate Agents in the United States by RealTrends, Ranking #723 in Florida Out of 232,000 Realtors
-
Are AI Crypto Trading Bots Suitable for Crypto Beginners? BulkQuant Launches an Automated Crypto Trading App
-
SKG Launches PS700 Neck Massager, Bringing Deep Kneading, Layered Heat, and Immersive Audio to Everyday Recovery
-
All In FutureTech Alliance Provides Strategic Updates: Hainan AIFA Digital Industrial Park, Silicon Photonics Compute Center Planning, and Cross-Border Optical Network Integration
-
Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress
-
Jura Provides Update on Dutch Attachment Proceedings
-
InterPrivate Investment Partners V, Inc. Announces Closing of $201.25 Million Initial Public Offering
-
McFarlane Lake Mining Provides Update on Investor Relations and Marketing Service Engagements
-
Argo Corporation Announces Closing of Strategic Investment
-
SHARE3DCAM Launches AI Engine Algorithm Upgrade in SHARE PointClouds Studio V2.5.0, Advancing the Complete Scan-to-Deliverable Workflow for AEC and Renovation Professionals
-
Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules
-
All-Round for Work & Play: KTC Dual-Mode Monitor H27P6 Adapts to Full-Scenario Needs
-
All-Round for Work & Play: KTC Dual-Mode Monitor H27P6 Adapts to Full-Scenario Needs
-
NatureU® Now Has Three Clinical Studies Publicly Registered on ClinicalTrials.gov as 56-Day PQQ Skin-Aging Study (NCT07571629) Joins Two Previously Published Peer-Reviewed Trials
-
Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (A
-
Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026
-
Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 S
-
Oban BioPharma Announces Presentation of Late-Breaking Abstract at ADA 2026 Highlighting OBT-676: A First-in-Class Small Molecule Combining Dual Amylin and Calcitonin Receptor Full Agonism (DACRA) wit
